Acunivive 90 Injection System and Ramucirumab

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Ramucirumab can cause bleeding and gastrointestinal perforation. Combining it with other medications that also have these effects such as ketorolac may increase the risk. In clinical studies, treatment with ramucirumab alone has been associated with severe and sometimes fatal hemorrhage. Rarely, gastrointestinal perforation has occurred, which is a potentially fatal condition and medical emergency where a hole forms all the way through the stomach or intestine. Except for daily low-dose aspirin to prevent heart attacks, chronic use of other similar analgesics (also known as nonsteroidal anti-inflammatory drugs, or NSAIDs) during treatment with ramucirumab has not been studied. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. You should seek immediate medical attention if you experience any unusual bleeding or bruising, or have other signs and symptoms of bleeding such as dizziness; lightheadedness; red or black, tarry stools; coughing up or vomiting fresh or dried blood that looks like coffee grounds; severe headache; and weakness. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Theoretical concerns exist that nonsteroid anti-inflammatory drugs (NSAIDs) and salicylates may potentiate the risk of bleeding and gastrointestinal perforation associated with ramucirumab therapy. Ramucirumab can cause bleeding, including severe and sometimes fatal hemorrhagic complications. In one clinical study, the incidence of severe bleeding was 3.4% for ramucirumab versus 2.6% for placebo. Ramucirumab can also increase the risk of gastrointestinal perforation. Four of 570 patients (0.7%) who received ramucirumab monotherapy in clinical trials experienced gastrointestinal perforation, which can be fatal. However, the risk of gastric hemorrhage and perforation during concomitant use of ramucirumab and NSAIDs is unknown, since patients with gastric cancer receiving NSAIDs (except low dose aspirin up to 325 mg/day) were generally excluded from clinical trials.

MANAGEMENT: Caution is advised if ramucirumab must be used with chronic NSAID or salicylate therapy. Close clinical and laboratory observation for bleeding complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools. Ramucirumab should be permanently discontinued in patients who experience severe bleeding or gastrointestinal perforation.

Acunivive 90 Injection System

Generic Name: ketorolac

Brand name: Sprix, Toradol

Synonyms: Ketorolac (nasal), Ketorolac (Nasal)

What is Acunivive 90 Injection System?

Ramucirumab

Generic Name: ramucirumab

Brand name: Cyramza

Synonyms: n.a.

What is Ramucirumab?